Compare Equinix Inc (EQIX) vs Sana Biotechnology Inc (SANA) Price & Performance

Equinix (EQIX) trades at $1,069.17, up 2.47% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 EPS of $4.83, beating estimates, and raised its long-term growth outlook amid strong AI infrastructure demand. Revenue grew to $9.22 billion in 2025, with net income margin improving to 15.63%. However, valuation multiples like P/E of 66.44 and EV/EBITDA of 27.58 are elevated, and net cash flow turned negative in 2025 due to heavy investing activities.

The outlook is supported by robust analyst sentiment with a $1,120 consensus price target and 74.51% buy ratings, but risks include high leverage with debt-to-asset ratio rising to 47.13% in 2025 and earnings misses in two of the last three quarters. Investors should weigh growth potential against valuation and execution risks.

SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.

The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.